| HOME >> MEDICINE >> TECHNOLOGY |
DURHAM, N.C., Sept. 16, 2011 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, announced today that investigators will present preliminary data for CMX001 in a late-breaker presentation at the 51st Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC, Chicago – September 17-20).
Genovefa Papanicolaou, M.D., Associate Member of Infectious Diseases Service at Memorial Sloan-Kettering Cancer Center and one of the lead investigators in Chimerix's ongoing Phase 2 cytomegalovirus (CMV) study, will give a presentation entitled, "CMX001 is not nephrotoxic or myelosuppressive in 183 patients with life threatening dsDNA infections including refractory Cytomegalovirus, Adenovirus, and BK Virus," on Sunday, September 18 at 8:30 am CDT. Immediately following Dr. Papanicolaou's presentation, Richard Whitley, M.D., Distinguished Professor at The University of Alabama at Birmingham, will present "New Antivirals for Herpes Viruses: What Can We Look Forward to and When?," which highlights CMX001. Both presentations are part of the "Herpes and Other Viruses" slide session that begins at 8:30 am CDT. In accordance with ICAAC embargo policy, these data remain under embargo until conclusion of the late-breaker session on Sunday, September 18 at 11:00 am CDT.
Data from Dr. Papanicolaou's presentation was generated as part of Chimerix's expanded access program, through which Chimerix has dosed over 300 subjects with CMX001 since March 2009, including 183 subjects under investigator-held Emergency Investigational New Drug applications (EINDs) or foreign equivalents at over 80 medical centers in the United States, Canada, Europe, and Israel. Through EINDs, CMX001 has been used for the treatment of a wide range of life-threatening infections caused by dsDNA viruses, including CMV, adenovirus (AdV), BK virus (BKV), Epstein Barr virus (EBV), herpes simplex v
'/>"/>
| SOURCE Chimerix, Inc. Copyright©2010 PR Newswire. All rights reserved |